TY - JOUR
T1 - Neurodevelopmental outcomes in preterm infants with retinopathy of prematurity
AU - Tan, Hao
AU - Blasco, Patricia
AU - Lewis, Tamorah
AU - Ostmo, Susan
AU - Chiang, Michael F.
AU - Campbell, John Peter
N1 - Funding Information:
Financial Support: JPC is supported by R01EY19474, R01EY031331, R21EY031883, and P30EY10572 from the National Institutes of Health (Bethesda, MD); and by unrestricted departmental funding and a Career Development Award from the Research to Prevent Blindness. JPC and PB receive research support from Genentech. TL is supported by a NICHD 1K23HD09136201A1 award and a Robert Wood Johnson Foundation Harold Amos Award. The sponsors / funding organizations had no role in the design or conduct of this research.
Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2021/9/1
Y1 - 2021/9/1
N2 - Over the past decade there has been a paradigm shift in the treatment of retinopathy of prematurity (ROP) with the introduction of antivascular endothelial growth factor (anti-VEGF) treatments. Anti-VEGF agents have the advantages of being easier to administer, requiring less anesthesia, having the potential for improved peripheral vision, and producing less refractive error than laser treatment. On the other hand, it is known that intravitreal administration of anti-VEGF agents lowers VEGF levels in the blood and raises the theoretical concern of intraocular anti-VEGF causing deleterious effects in other organ systems, including the brain. As a result, there has been increased attention recently on neurodevelopmental outcomes in infants treated with anti-VEGF agents. These studies should be put into context with what is known about systemic comorbidities, socioeconomic influences, and the effects of extreme prematurity itself on neurodevelopmental outcomes. We summarize what is known about neurodevelopmental outcomes in extremely preterm infants with ROP, discuss the implications for determining the neurodevelopmental status using neurodevelopmental testing as well as other indicators, and review the existing literature relating to neurodevelopmental outcomes in babies treated for ROP.
AB - Over the past decade there has been a paradigm shift in the treatment of retinopathy of prematurity (ROP) with the introduction of antivascular endothelial growth factor (anti-VEGF) treatments. Anti-VEGF agents have the advantages of being easier to administer, requiring less anesthesia, having the potential for improved peripheral vision, and producing less refractive error than laser treatment. On the other hand, it is known that intravitreal administration of anti-VEGF agents lowers VEGF levels in the blood and raises the theoretical concern of intraocular anti-VEGF causing deleterious effects in other organ systems, including the brain. As a result, there has been increased attention recently on neurodevelopmental outcomes in infants treated with anti-VEGF agents. These studies should be put into context with what is known about systemic comorbidities, socioeconomic influences, and the effects of extreme prematurity itself on neurodevelopmental outcomes. We summarize what is known about neurodevelopmental outcomes in extremely preterm infants with ROP, discuss the implications for determining the neurodevelopmental status using neurodevelopmental testing as well as other indicators, and review the existing literature relating to neurodevelopmental outcomes in babies treated for ROP.
KW - Neurodevelopment
KW - anti-VEGF
KW - bevacizumab
KW - pediatric retina
KW - retinopathy of prematurity
UR - http://www.scopus.com/inward/record.url?scp=85103939048&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85103939048&partnerID=8YFLogxK
U2 - 10.1016/j.survophthal.2021.02.012
DO - 10.1016/j.survophthal.2021.02.012
M3 - Review article
C2 - 33667496
AN - SCOPUS:85103939048
SN - 0039-6257
VL - 66
SP - 877
EP - 891
JO - Survey of Ophthalmology
JF - Survey of Ophthalmology
IS - 5
ER -